• Vaccine Name: F. tularensis vaccine rLm/iglC
• Target Pathogen: Francisella tularensis
• Target Disease: Tularemia
• Vaccine Ontology ID: VO_0000431
• Type: Recombinant vector vaccine
• Status: Research
• Antigen: F. tularensis intracellular growth locus, subunit C (iglC)
• IglC1 gene engineering:
  • Type: DNA vaccine construction
  • Description: Constructed recombinant L. monocytogenes (rLm) vaccines stably expressing seven F. tularensis proteins including IglC (rLm/iglC) (Jia et al., 2009).
  • Detailed Gene Information: Click Here.
• IglC2 gene engineering:
  • Type: Recombinant vector construction
  • Description: Constructed recombinant L. monocytogenes (rLm) vaccines stably expressing seven F. tularensis proteins including IglC (rLm/iglC) (Jia et al., 2009).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intradermal injection (i.d.)
• Description: Seven F. tularensis proteins including IglC (rLm/iglC) were expressed in recombinant L. monocytogenes (rLm) vaccines (Jia et al., 2009). These 7 F. tularensis proteins are: AcpA, Bfr, DnaK, GroEL, IglC, Pld and KatG from SchuS4 strain.

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Six groups of 8 mice were sham-immunized or immunized with LVS or rLm vaccines at weeks 0 and 4 (Jia et al., 2009).
• Challenge Protocol: At week 8, mice were anesthetized with Ketamine/Xylazine, challenged i.n. with 4400 CFU of LVS, and monitored for survival for up to 3 weeks after challenge. Intranasal challenge with 65× LD50 of LVS. Groups of mice were sham-immunized or immunized i.d. twice at weeks 0 and 4 with 5 × 10^4 CFU LVS or 1 × 10^6 CFU of rLmΔactA (vector), rLm/iglC, rLm/katG or rLm/iglC plus rLm/katG (Jia et al., 2009).
• Efficacy: Mice immunized with rLm/iglC were protected against lethal challenge with F. tularensis LVS administered by the intranasal route, a route chosen to mimic airborne infection, and, most importantly, against aerosol challenge with the highly virulent Type A F. tularensis SchuS4 strain (Jia et al., 2009).